Last week, the FDA approved Biogen’s Alzheimer’s drug candidate, aducanumab (marketed as Aduhelm). This approval looks likely to be a watershed moment for the biotech industry. The shares of Biogen were halted for the announcement. And as anticipated, they popped once trading resumed.
![](https://www.riverstonewp.com/wp-content/uploads/2021/06/healthcare-a-v0Q8ni.jpeg)